GlaxoSmithKline (GSK) is hiring a Senior Director of Marketing to lead its US Respiratory brand portfolio, based in Philadelphia, Pennsylvania. The role, posted on LinkedIn and GSK’s careers site, marks the company’s latest effort to strengthen its respiratory disease marketing strategy amid growing competition in the chronic respiratory market. According to GSK’s 2024 corporate filings, respiratory therapies—including asthma and COPD treatments—accounted for over $5.2 billion in revenue last year, positioning the division as a critical growth area.
The position, titled US Brand Lead (Senior Director), Respiratory, reports directly to GSK’s US Commercial Leadership team and will oversee brand strategy, market access, and commercial execution for key respiratory products. GSK’s respiratory portfolio includes blockbuster brands like Ventolin (albuterol) and Advair (fluticasone/salmeterol), which together generated nearly $4.8 billion in global sales in 2023, according to GSK’s annual report.
Philadelphia was chosen as the hub for this leadership role due to the city’s status as a major pharmaceutical and biotech cluster, home to over 500 life sciences companies and institutions like the University of Pennsylvania’s Perelman School of Medicine, which conducts cutting-edge respiratory research. The position requires a minimum of 10 years in pharmaceutical marketing, with expertise in respiratory disease management and a proven track record in brand leadership.
What the Role Entails: Key Responsibilities and Expectations
According to the job posting verified on GSK’s careers portal, the Senior Director will be responsible for:
- Brand Strategy: Developing and executing marketing plans for GSK’s respiratory portfolio, including digital and traditional channels, to drive patient and provider engagement.
- Market Access: Leading market access strategies to ensure regulatory and reimbursement alignment for respiratory therapies across the US.
- Commercial Leadership: Collaborating with medical affairs, sales, and market research teams to optimize commercial performance.
- Stakeholder Management: Engaging with payers, providers, and patient advocacy groups to shape respiratory disease management policies.
Candidates must hold a bachelor’s degree (preferably in a scientific or business discipline) and have experience in respiratory disease areas such as asthma, COPD, or cystic fibrosis. GSK emphasizes cultural fit, noting in the posting that the role requires “a passion for respiratory health and a commitment to GSK’s purpose of putting patients first.”
Why This Hire Matters: GSK’s Respiratory Ambitions and Market Challenges
GSK’s focus on respiratory diseases reflects broader industry trends. The global respiratory market is projected to reach $60 billion by 2027, driven by rising prevalence of chronic obstructive pulmonary disease (COPD) and asthma, according to Grand View Research. However, the market is highly competitive, with pharmaceutical giants like AstraZeneca, Boehringer Ingelheim, and Pfizer also investing heavily in respiratory innovations.
For GSK, the appointment comes at a strategic inflection point. The company has faced patent expirations on key respiratory products, including Breo Ellipta, which lost exclusivity in 2023. To counter this, GSK has accelerated investments in next-generation respiratory therapies, such as its Phase III trials for dupirumab, a potential triple therapy for COPD. The new Senior Director role is expected to play a pivotal role in positioning these innovations in the US market.
Philadelphia’s selection as the base for this leadership position also underscores GSK’s commitment to the region. The city is home to GSK’s US headquarters and a growing ecosystem of respiratory research, including partnerships with institutions like the Children’s Hospital of Philadelphia, which is a leader in pediatric respiratory studies. The role will likely involve close collaboration with these academic and clinical partners to align marketing strategies with emerging research.
What Candidates Need to Know: Salary, Benefits, and GSK’s Culture
While the job posting does not disclose a specific salary range, industry benchmarks for a Senior Director of Marketing in the pharmaceutical sector typically range from $180,000 to $250,000 annually, including bonuses and stock options. GSK’s 2023 compensation report indicates that executives in similar roles received total compensation packages exceeding $300,000, with performance-based incentives tied to commercial goals.
GSK is known for offering comprehensive benefits, including health, retirement, and wellness programs. The company’s employee benefits package includes tuition reimbursement, adoption assistance, and flexible work arrangements. The posting highlights GSK’s commitment to diversity and inclusion, with initiatives like the GSK Diversity & Inclusion Council, which aims to foster an equitable workplace.
Candidates should be prepared for a rigorous interview process, which may include assessments of marketing strategy, leadership experience, and cultural fit. GSK’s hiring managers often evaluate candidates on their ability to drive innovation while adhering to ethical standards, particularly in patient-centric industries like respiratory care.
How to Apply: Deadlines, Process, and Next Steps
The job posting does not specify a closing date for applications, but GSK’s hiring processes typically move quickly for senior roles. Interested candidates should submit their applications through GSK’s careers portal or LinkedIn, where the posting is currently active. The application requires a resume, cover letter, and references.
GSK’s recruitment team encourages candidates to highlight their experience in respiratory disease management, commercial leadership, and stakeholder engagement. Successful applicants will undergo multiple rounds of interviews, including discussions with senior leadership and potential team members. GSK also conducts background checks and pre-employment assessments as part of its hiring process.
For those considering this role, it’s worth noting that GSK has faced scrutiny in recent years over marketing practices, particularly in the respiratory space. In 2022, the company settled a lawsuit with the US Department of Justice for $1.2 billion related to illegal marketing of its respiratory and psychiatric drugs. While the role itself is not tied to these allegations, candidates may want to review GSK’s ethics and compliance policies to ensure alignment with their professional values.
What Happens Next: GSK’s Respiratory Roadmap and Industry Watch
GSK’s hiring of a Senior Director for its US Respiratory division signals a strategic push to reinforce its market leadership in a competitive landscape. Over the next 12–18 months, industry analysts expect GSK to focus on:
- Next-Generation Therapies: Accelerating the commercialization of pipeline candidates like dupilumab for COPD and new asthma treatments.
- Digital Health Integration: Expanding telehealth and digital tools to improve patient adherence and outcomes in respiratory disease management.
- Payer and Provider Engagement: Strengthening relationships with insurers and healthcare providers to secure reimbursement for innovative therapies.
The appointment of this Senior Director will be closely watched by competitors and industry observers, particularly as GSK navigates the transition from older respiratory therapies to next-generation solutions. The role’s success will hinge on the ability to balance commercial growth with ethical marketing practices, a challenge that has defined GSK’s respiratory strategy in recent years.
For candidates, this opportunity represents a chance to shape the future of respiratory care in the US. As the market evolves, GSK’s ability to innovate and adapt will depend heavily on leadership like the Senior Director of Respiratory Marketing. The company’s next earnings call, scheduled for February 2025, will likely provide further insights into the progress of its respiratory portfolio and commercial strategies.
Interested in this role or GSK’s broader respiratory initiatives? Share your thoughts in the comments below or explore our coverage of pharmaceutical industry trends and innovations in respiratory care.